RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adaptimmune Therapeutics Stock

Adaptimmune Therapeutics P/S 2024

Adaptimmune Therapeutics P/S

7.64

Ticker

ADAP

ISIN

US00653A1079

WKN

A14SUX

As of Nov 19, 2024, Adaptimmune Therapeutics's P/S ratio stood at 7.64, a -64.97% change from the 21.81 P/S ratio recorded in the previous year.

The Adaptimmune Therapeutics P/S history

Adaptimmune Therapeutics Aktienanalyse

What does Adaptimmune Therapeutics do?

Adaptimmune Therapeutics PLC is a biotechnology company specializing in the development of immunotherapies against cancer. The company was founded in 2008 and is headquartered in Oxfordshire, England. Adaptimmune focuses on harnessing the human immune system to target and destroy cancer cells. The company's business model primarily revolves around the research and development of therapeutic products for different types of cancer. It develops and utilizes T-cell receptor (TCR) therapies to specifically target cancer cells. TCRs are proteins on T-cells that can recognize and kill cancer cells. Adaptimmune harnesses this property of TCRs to develop specific receptors targeted against certain types of cancer. Adaptimmune has three different business segments: oncology, autoimmune diseases, and infections. However, the focus is primarily on oncology. In this area, Adaptimmune concentrates on developing TCR products for various types of cancer such as pancreatic cancer, esophageal cancer, and lung cancer. One of Adaptimmune's key products is the T-cell therapy known as SPEAR (Specific Peptide Enhanced Affinity Receptor), which is individually developed for each patient. This therapy utilizes TCRs targeting specific tumor cells. The TCRs are optimized so that the body's own T-cells can precisely recognize and destroy the cancer cells. SPEAR has already shown promising results in a clinical study for melanoma patients. Another important product of Adaptimmune is ADP-A2M4. This immunotherapy also utilizes TCRs developed to target specific cancer cells. ADP-A2M4 is currently in Phase II clinical trials for advanced or metastatic esophageal cancer or gastric cancer. Adaptimmune also has partnerships with other companies and organizations such as GSK, NY-ESO-1, Universal Cells, and the MD Anderson Cancer Center. This collaboration expands the company's portfolio and enables the development of innovative immunotherapies. Overall, Adaptimmune's goal is to develop innovative TCR products for the treatment of various types of cancer. With its focus on immunotherapies, the company has created unique solutions to mobilize the human immune system specifically against cancer. Adaptimmune has the potential to revolutionize cancer treatment and improve the lives of millions of people. Adaptimmune Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Adaptimmune Therapeutics's P/S Ratio

Adaptimmune Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Adaptimmune Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Adaptimmune Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Adaptimmune Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Adaptimmune Therapeutics stock

What is the price-to-earnings ratio of Adaptimmune Therapeutics?

The price-earnings ratio of Adaptimmune Therapeutics is currently 7.64.

How has the price-earnings ratio of Adaptimmune Therapeutics changed compared to last year?

The price-to-earnings ratio of Adaptimmune Therapeutics has increased by -64.97% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Adaptimmune Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Adaptimmune Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Adaptimmune Therapeutics affect the company?

An increase in the price-earnings ratio of Adaptimmune Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Adaptimmune Therapeutics affect the company?

A decrease in the price-earnings ratio of Adaptimmune Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Adaptimmune Therapeutics?

Some factors that influence the price-earnings ratio of Adaptimmune Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Adaptimmune Therapeutics pay?

Over the past 12 months, Adaptimmune Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptimmune Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptimmune Therapeutics?

The current dividend yield of Adaptimmune Therapeutics is .

When does Adaptimmune Therapeutics pay dividends?

Adaptimmune Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptimmune Therapeutics?

Adaptimmune Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Adaptimmune Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptimmune Therapeutics located?

Adaptimmune Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptimmune Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptimmune Therapeutics from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Adaptimmune Therapeutics pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Adaptimmune Therapeutics in the year 2023?

In the year 2023, Adaptimmune Therapeutics distributed 0 USD as dividends.

In which currency does Adaptimmune Therapeutics pay out the dividend?

The dividends of Adaptimmune Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Adaptimmune Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Adaptimmune Therapeutics

Our stock analysis for Adaptimmune Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptimmune Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.